Lipodystrophy syndrome: The morphologic and metabolic effects of antiretroviral therapy in HIV infection

被引：14

作者：

Norris, A ^{[1
]}

Dreher, HM

机构：

[1] Drexel Univ, Partnership Comprehens Care Practice HIV Clin, Philadelphia, PA 19104 USA

[2] Drexel Univ, Coll Nursing & Hlth Profess, Doctoral Nursing Program, Philadelphia, PA USA

来源：

JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE | 2004年 / 15卷 / 06期

关键词：

lipodystrophy syndrome; lipoatrophy; hyperlipidemia; insulin resistance;

D O I：

10.1177/1055329004271187

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Widespread use of highly active antiretroviral therapy (HAART) to manage HIV infection is now associated with the development of lipodystrophy syndrome. This syndrome is a combination of such morphologic and metabolic changes as hyperlipidemia, fat redistribution, and insulin resistance. Although many of the long-term effects of HAART have not been fully recognized, it is thought that lipodystrophy syndrome may now contribute to early-onset hypercholesterolemia, heart disease, and diabetes, and may have a negative psychological impact on the individual living with HIV infection.

引用

页码：46 / 64

页数：19

共 50 条

[1] Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection
Holstein, A
Plaschke, A
Egberts, EH
[J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2001, 109 (08) : 389 - 392
[2] Metabolic complications of HIV-1 antiretroviral therapy:: The lipodystrophy syndrome
Borderi, M
Verucchi, G
Tadolini, M
Spinosa, S
Fortunato, L
Talò, S
Chiodo, F
[J]. MICROBIOLOGICA, 2001, 24 (03): : 303 - 315
[3] Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy
Vidal, Francesc
Domingo, Pere
Vilades, Consuelo
Peraire, Joaquim
Arnedo, Mireia
Alcami, Jose
Leal, Manuel
Villarroya, Francesc
Ma Gatell, Josep
[J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (11) : 1365 - 1382
[4] Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy
Estrada, Vicente
Martinez-Larrad, Maria Teresa
Gonzalez-Sanchez, Jose Luis
de Villar, Noemi G. P.
Zabena, Carina
Fernandez, Cristina
Serrano-Rios, Manuel
[J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2006, 55 (07): : 940 - 945
[5] Lipodystrophy following antiretroviral therapy of primary HIV infection
Miller, J
Carr, A
Smith, D
Emery, S
Law, MG
Grey, P
Cooper, DA
[J]. AIDS, 2000, 14 (15) : 2406 - 2407
[6] Antiretroviral therapy and the lipodystrophy syndrome
John, M
Nolan, D
Mallal, S
[J]. ANTIVIRAL THERAPY, 2001, 6 (01) : 9 - 20
[7] Targets of Metabolic Toxicity of HIV Antiretroviral Drugs: The Multiple Roads to Lipodystrophy and Metabolic Syndrome
Domingo, Pere
Villarroya, Francesc
[J]. CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (30) : 3337 - 3338
[8] The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy
Hansen, B. R.
Petersen, J.
Haugaard, S. B.
Madsbad, S.
Obel, N.
Suzuki, Y.
Andersen, O.
[J]. HIV MEDICINE, 2009, 10 (06) : 378 - 387
[9] Metabolic profile, anthropometric and lipodystrophy in people living with HIV/AIDS in antiretroviral therapy
Conceicao da Silva, Iana
Sampaio, Ethiane
Almeida, Maiara
Ney Freire, Andre
Ramos, Lilian
Barreto Medeiros, Jairza Maria
[J]. NUTRICION CLINICA Y DIETETICA HOSPITALARIA, 2016, 36 (03): : 38 - 44
[10] Metabolic and morphologic disorders in patients treated with highly active antiretroviral therapy since primary HIV infection
Narciso, P
Tozzi, V
D'Offizi, G
De Carli, G
Orchi, N
Galati, V
Vincenzi, L
Bellagamba, R
Carvelli, C
Puro, V
[J]. HIV-ASSOCIATED CARDIOVASCULAR DISEASE: CLINICAL AND BIOLOGICAL INSIGHTS, 2001, 946 : 214 - 222

← 1 2 3 4 5 →